pure bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. pure's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (sdc)- based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. patented sdc is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. as a platform technology, sdc is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. pure is headquartered in el cajon, california (san diego metropolitan area). additional information on pure is available at www.purebio.com.
Company profile
Ticker
PURE
Exchange
Website
CEO
Tom Y. Lee
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Element Solutions • Cabot • Orion S.A • Versum Materials • WD-40 • Arq • GlyEco • Flexible Solutions International • Flotek Industries • ASP Isotopes ...
Former names
INNOVATIVE MEDICAL SERVICES, PURE BIOSCIENCE
SEC CIK
Corporate docs
IRS number
330530289
PURE stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
27 Mar 24
10-Q
2024 Q2
Quarterly report
18 Mar 24
8-K
PURE Bioscience Reports Fiscal Second Quarter 2024
18 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
26 Feb 24
DEF 14A
Definitive proxy
10 Jan 24
PRE 14A
Preliminary proxy
19 Dec 23
10-Q
2024 Q1
Quarterly report
14 Dec 23
8-K
PURE Bioscience Reports Fiscal First Quarter 2024
14 Dec 23
10-K
2023 FY
Annual report
30 Oct 23
8-K
PURE Bioscience Reports Fiscal 2023
30 Oct 23
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jul 23 | Jul 22 | Jul 21 | Jul 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm | 1.52 mm |
Cash burn (monthly) | (no burn) | 84.33 k | 237.00 k | 305.67 k | 146.67 k | 234.67 k |
Cash used (since last report) | n/a | 494.98 k | 1.39 mm | 1.79 mm | 860.84 k | 1.38 mm |
Cash remaining | n/a | 1.02 mm | 123.96 k | -279.07 k | 654.16 k | 137.66 k |
Runway (months of cash) | n/a | 12.1 | 0.5 | -0.9 | 4.5 | 0.6 |
Institutional ownership, Q3 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.00 k |
Total shares | 13.83 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kirr Marbach & Co | 13.83 k | $5.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Aug 23 | Robert F Bartlett | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 150,000 | 18.00 k | 150,000 |
1 Aug 23 | Bernard Blotner | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 125,000 | 15.00 k | 125,000 |
1 Aug 23 | Chen Ivan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 150,000 | 18.00 k | 150,000 |
1 Aug 23 | Myers Thomas Richard | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 150,000 | 18.00 k | 150,000 |
1 Aug 23 | David Rendall | Stock Option Common Stock | Grant | Acquire A | No | No | 0.12 | 125,000 | 15.00 k | 125,000 |